摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3,4-二氯苯基)-N-甲基-N-[(1S,2S)-2-(1-吡咯烷基)环己基]乙酰胺盐酸盐(1:1) | 67198-19-0

中文名称
2-(3,4-二氯苯基)-N-甲基-N-[(1S,2S)-2-(1-吡咯烷基)环己基]乙酰胺盐酸盐(1:1)
中文别名
——
英文名称
(-)-trans-(1S,2S)-U-50488
英文别名
(-)-U 50488;trans-(1S,2S)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide;(1S,2S)-N-methyl-N-[2-(pyrrolidin-1-yl)cyclohexyl]-2-(3,4-dichlorophenyl)acetamide;2-(3,4-dichlorophenyl)-N-methyl-N-[(1S,2S)-2-pyrrolidinocyclohexyl]acetamide;(-)-(trans)-(1S,2S)-U50,488;U-(-)-50488;2-(3,4-dichlorophenyl)-N-methyl-N-[(1S,2S)-2-(1-pyrrolidinyl)cyclohexyl]acetamide;2-(3,4-dichlorophenyl)-N-methyl-N-[(1S,2S)-2-pyrrolidin-1-ylcyclohexyl]acetamide
2-(3,4-二氯苯基)-N-甲基-N-[(1S,2S)-2-(1-吡咯烷基)环己基]乙酰胺盐酸盐(1:1)化学式
CAS
67198-19-0
化学式
C19H26Cl2N2O
mdl
——
分子量
369.334
InChiKey
VQLPLYSROCPWFF-ROUUACIJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    496.6±45.0 °C(Predicted)
  • 密度:
    1.23±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.63
  • 拓扑面积:
    23.6
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:a8ba52c7fac01d723a3cd1894bbccb6a
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and receptor binding of enantiomeric N-substituted cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamines as high-affinity .sigma. receptor ligands
    摘要:
    N-Alkyl-substituted derivatives of (+)- and (-)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine have been synthesized in nine steps in a stereospecific manner starting from cyclohexene oxide. The key step in the reaction sequence involved catalytic hydrogenation of oxime 8 in the presence of PtO2 and AcOH to give the cis diamine (+/-)-7. Most of the compounds in this series exhibited very high affinity at sigma-receptors when tested against [H-3]-(+)-3-PPP, and in general it was observed that the 1R,2S enantiomers bound more potently to sigma-receptors than their corresponding 1S,2R enantiomers. The most potent sigma-ligand found in this class was the unsubstituted derivative (1R,2S)-(-)-4, which exhibited an affinity constant of 0.49 nM. This compound was also found to be very selective for sigma-receptors. It exhibited little or no affinity for kappa-opioid, PCP, and dopamine-D2 receptors. It was also demonstrated that the cis configuration as opposed to the trans configuration of (+)- and (-)-5 was necessary for a higher sigma-receptor affinity.
    DOI:
    10.1021/jm00114a015
  • 作为产物:
    参考文献:
    名称:
    阿片受体激动剂 U50488 抗布氏锥虫活性的优化
    摘要:
    针对培养的布氏锥虫(非洲昏睡病的病原体)筛选 Sigma-Aldrich 药理活性化合物库 (LOPAC) ,鉴定出许多对哺乳动物细胞具有选择性抗增殖活性的化合物。其中包括 (+)-(1 R ,2 R )-U50488,这是一种弱阿片类激动剂,EC 50值为 59 n M,如我们之前报道的布氏锥虫体外试验所测定。本文描述了对 U50488 关键结构元素的修饰,以研究结构-活性关系 (SAR) 并优化该化合物的抗增殖活性和药代动力学特性。
    DOI:
    10.1002/cmdc.201100278
点击查看最新优质反应信息

文献信息

  • Chemoenzymatic Preparation of Optically Active<i>trans</i>-Cyclohexane-1,2-diamine Derivatives: An Efficient Synthesis of the Analgesic U-(−)-50,488
    作者:Javier González-Sabín、Vicente Gotor、Francisca Rebolledo
    DOI:10.1002/chem.200400607
    日期:2004.11.19
    Stereoespecific syntheses of (+/-)-trans-N,N-cyclohexane-1,2-diamines ((+/-)-4 a-g) were carried out from the corresponding (+/-)-trans-N,N-dialkylaminocyclohexanols by successive treatment with mesyl chloride and aqueous ammonia. The stereochemical outcome indicates the formation of a meso-aziridinium ion intermediate. Kinetic resolutions of diamines (+/-)-4 were efficiently accomplished in aminolysis
    (+/-)-反-N,N-环己烷-1,2-二胺((+/-)-4 ag)的立体定向合成是从相应的(+/-)-反-N,N-通过连续用甲磺酰氯和氨水处理二烷基氨基环己醇。立体化学结果表明形成了中叠氮鎓离子中间体。二胺(+/-)-4的动力学拆分可有效地完成南极假丝酵母脂肪酶B催化的氨解反应,其中乙酸乙酯为溶剂和酰基供体。分离出的乙酰胺和其余的二胺作为苄氧羰基衍生物,具有很高的ee值(92-99%)。一种氨基甲酸酯用作镇痛剂U-(-)-50,488的前体。
  • OPIOID RECEPTOR LIGANDS
    申请人:Bohn Laura M.
    公开号:US20090088466A1
    公开(公告)日:2009-04-02
    The invention provides novel compounds of formula (I), (II), (III), and (IV). The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to an animal in need of treatment. The invention also provides therapeutic methods for the use of compounds of formula (V), as well as methods for treating diseases by administering such compounds.
    本发明提供了化合物(I)、(II)、(III)和(IV)的新型化合物。本发明还提供了包含这些化合物的药物组合物,以及通过向需要治疗的动物施用这些化合物来治疗与阿片受体功能相关的疾病的方法。本发明还提供了化合物(V)的治疗方法,以及通过施用这些化合物来治疗疾病的方法。
  • Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
    申请人:Kõster Hubert
    公开号:US20100248264A1
    公开(公告)日:2010-09-30
    Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.
    提供了捕获化合物及其集合以及使用这些化合物进行生物分子分析的方法。特别地,提供了用于分析复杂蛋白质混合物(如蛋白质组)的集合、化合物和方法。这些化合物是多功能试剂,可用于分离和分离复杂的蛋白质混合物。还提供了执行这些方法的自动化系统。
  • 2-Aminocycloalkenyl carboxamides and their tritiated 2-aminocycloalkyl carboxamide derivatives
    申请人:THE UPJOHN COMPANY
    公开号:EP0129991A1
    公开(公告)日:1985-01-02
    2-Aminocycloalkenyl benzamides and phenylacet- amides, e.g. 3,4-dichloro-N-methyl-N-[6-(1- pyrrolidinyl) -3-cyclohexenyl]benzeneacetamide, and their salts, are of potential value as analgesics. The corresponding tritiated, saturated compounds are also new, and of utility as radio-labelled compounds for pharmacological and metabolic studies in animals.
    2-Aminocycloalkenyl benzamides and phenylacet- amides, e.g. 3,4-dichloro-N-methyl-N-[6-(1- pyrrolidinyl) -3-cyclohexenyl]benzeneacetamide, and their salts, are of potential value as analgesics.相应的三价饱和化合物也是一种新化合物,可作为放射性标记化合物用于动物药理和代谢研究。
  • 3,4-Dichloro-N-[2-(2,5-dihydro-1H-pyrrol-1-yl)cyclohexyl]-N-methylbenzeneacetamide
    申请人:THE UPJOHN COMPANY
    公开号:EP0126612A1
    公开(公告)日:1984-11-28
    N-[2-(2,5-dihydro-1H-pyrrol-1-yl)cycloaliphatic]benzeneacetamide and -benzamide compounds, e.g. (1α,2β)-(±)-3,4--dichloro-N-(2-(2,5-dihydro-1 H-pyrrol-1-yl)cyclohexyl]-N-me- thylbenzeneacetamide, and salts thereof, which can have useful analgesic activity, low abuse or physical dependence liability properties.
    N-[2-(2,5-二氢-1H-吡咯-1-基)环脂族]苯乙酰胺和-苯甲酰胺化合物,例如(1α,2β)-(±)-3,4-二氯-N-(2-(2,5-二氢-1H-吡咯-1-基)环己基]-N-甲基-苯乙酰胺及其盐,它们具有有用的镇痛活性、低滥用或身体依赖性。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐